ALLMedicine™ Langerhans Cell Histiocytosis Center

Mar 18th, 2023 - Oncocytes are a component of many metaplastic and neoplastic lesions throughout the head and neck area, primarily originating in salivary/seromucinous glands and the thyroid gland. In addition, other lesions can contain cells that mimic oncocytes ...

Mar 18th, 2023 - Oral ulcers represent a full thickness loss of the mucosal epithelium leading to exposure of the submucosal connective tissue. These are common and usually self-limited lesions, although they may sometimes result from neoplasms, most commonly squa...

Mar 17th, 2023 - Langerhans cell histiocytosis (LCH) is a potentially life-threatening inflammatory myeloid neoplasia linked to paediatric neurodegeneration, whereby transformed LCH cells form agglomerated lesions in various organs. Although MAP-kinase pathway mut...

Mar 10th, 2023 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...

Mar 10th, 2023 - Rosai-Dorfman disease (RDD) is a rare benign non-langerhans cell histiocytosis, mainly involving lymph nodes and skin. It is even rarer occurring only in central airway of lung and in diffuse form. Central airway RDD is similar to malignant tumor ...

Sep 2nd, 2019 - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by ...

Mar 10th, 2023 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...

Mar 9th, 2023 - PRIMARY OBJECTIVE: I. To determine overall response rate (ORR) for children and young adults with relapsed or refractory Langerhans cell histiocytosis (LCH) treated with tovorafenib (DAY101) after 2 cycles. SECONDARY OBJECTIVES: I. To determine na...

Dec 15th, 2022 - Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontane...

Sep 29th, 2022 - This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention, to learn whether the drug works in treating a specific disease, in this case, clofarabine to treat LCH. "Investig...

Sep 19th, 2022 - PRIMARY OBJECTIVES: I. To comprehensively characterize germline variants in SMAD6 and their association with LCH. II. To identify novel germline variants associated with LCH. III.To determine the role of genetic ancestry on LCH-related somatic mut...

Jan 30th, 2023 - A woman in her late 40s presented with painful ulcers in her groin and armpits that hadn't healed in 3 years, an Indian group reported in JAMA Dermatology. The woman explained that when the sores first appeared, they were just itchy, oozing, reddi...

Nov 4th, 2022 - The annual price of newly launched cancer drugs has increased 53% over the last 5 years, according to a report by U.S. Rep. Katie Porter (D-Calif.). (Reuters) A survey of large employers found that cancer has become the top driver of employer heal...

Nov 2nd, 2022 - The FDA has approved cobimetinib (Cotellic) for the treatment of adult patients with histiocytic neoplasms, which include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis.1,2 The regulatory decision was based on d...

Dec 1st, 2021 - Guidelines for the treatment of Langerhans cell histiocytosis (LCH) were published in November 2021 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network.[1] Decisions regarding treatment of LC...

Oct 6th, 2021 - In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstrea...